RET fusion-positive non-small-cell lung cancer: lines of therapy
2 standard-of-care settings across 1 lines and 2 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
Advanced, first line
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Advanced, first line | Selpercatinib (LIBRETTO-431) as preferred; pralsetinib as an alternative. | NCCN Guidelines: Non-Small Cell Lung Cancer | 90 | |
| RET | Advanced, after a RET inhibitor | Platinum-pemetrexed with or without pembrolizumab; clinical trial of a next-generation RET inhibitor; local radiotherapy for oligoprogression. | NCCN Guidelines: Non-Small Cell Lung Cancer | 98 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.